237 related articles for article (PubMed ID: 19948454)
1. Metastatic renal cell carcinoma: current standards of care.
Thompson JA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():8-12. PubMed ID: 19948454
[TBL] [Abstract][Full Text] [Related]
2. Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Moldawer NP; Figlin R
Oncol Nurs Forum; 2008 Jul; 35(4):699-708. PubMed ID: 18591174
[TBL] [Abstract][Full Text] [Related]
3. An update on targeted therapy in metastatic renal cell carcinoma.
Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
[TBL] [Abstract][Full Text] [Related]
4. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Bellmunt J; Calvo E; Castellano D; Climent MA; Esteban E; García del Muro X; González-Larriba JL; Maroto P; Trigo JM
Cancer Chemother Pharmacol; 2009 Mar; 63 Suppl 1():S1-13. PubMed ID: 19259675
[TBL] [Abstract][Full Text] [Related]
5. Present state of target therapy for disseminated renal cell carcinoma.
Waalkes S; Kramer M; Herrmann TR; Schrader AJ; Kuczyk MA; Merseburger AS
Immunotherapy; 2010 May; 2(3):393-8. PubMed ID: 20635903
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of metastatic renal cell carcinoma].
Thuret R; Maurin C; Sun M; Perrotte P; Karakiewicz PI
Prog Urol; 2011 Apr; 21(4):233-44. PubMed ID: 21482396
[TBL] [Abstract][Full Text] [Related]
7. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
[TBL] [Abstract][Full Text] [Related]
8. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
[TBL] [Abstract][Full Text] [Related]
9. Systemic therapy for metastatic renal cell carcinoma.
Kroog GS; Motzer RJ
Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
[TBL] [Abstract][Full Text] [Related]
10. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
11. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Biedrzycki BA
ONS News; 2006; 21(8 Suppl):21-2. PubMed ID: 16925136
[No Abstract] [Full Text] [Related]
13. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Di Lorenzo G; Casciano R; Malangone E; Buonerba C; Sherman S; Willet J; Wang X; Liu Z; De Placido S
Expert Opin Pharmacother; 2011 Jul; 12(10):1491-7. PubMed ID: 21599551
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Hutson TE
Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Pouessel D; Culine S
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in metastatic renal cancer in 2009.
Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Mizutani Y
Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
19. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Rini BI
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
